Giulia Notini
@NotiniGiulia
Food lover. Travel buff. Series addicted. Professional Procrastinator 🇮🇹 Oncology Resident @OspedaleSanRaffaele 🩺
1/4 📢Calling all T-Dxd prescribers!💉 Out now in @FrontOncology our real-world study on the impact of antiemetic prophylaxis in patients treated with T-DXd highlighted the efficacy of the three-drug regimen (with NK1RA) doi.org/10.3389/fonc.2… @LLicata88 @BianchiniGP 🧵👇🏻👇🏻
🔥Impressed by PATINA trial results? 👉 the longest mPFS ever in breast cancer (44 mths) Unexpected? Not really - Our study (👇👇) explain the biological rational - Supportive clinical trials (NA-PHER2, PERTAIN) ❗️CLEOPATRA trial did not allow ET maintenance @SABCSSanAntonio
📢Proud to see our work just published in @CCC_AACR. Resistance to drugs targeting ER (fulvestrant) and HER2 (trastuzumab+/-pertuzumab) can be bypassed by co-targeting CDK4/6 (palbocilib), enhancing transition from quiescence to sustained senescence 👇👇 pubmed.ncbi.nlm.nih.gov/35254385/
Excited to share our latest publication on @JAMANetworkOpen : "Completion rate and positive results reporting among immunotherapy trials in breast cancer, 2004-2023.” #BreastCancerResearch @OncoAlert @SanRaffaeleMI 👇Check out some key insights below
Just out in Cancer Treatment Reviews our manuscript on how to navigate the practical challenges in #immunotherapy for #mTNBC that cannot be addressed by clinical trials data 🌟What a pleasure joining this stellar team!🌟 @BianchiniGP @curijoey @JavierCortesMD @lajos_pusztai
Congrats, major effort! 👏🔝@CarmenCriscit
🙌Just out on @JAMAonc our review on PARPi for #breastcancer Many steps have been made in the last 20 yrs; a vast amount is left waiting to be explored. Great team effort led by @DFCI_BreastOnc and @IEOufficiale. Link 👉 jamanetwork.com/journals/jamao…
📢1/10 Out on @Nature our work ‘Spatial predictors of immunotherapy response in triple-negative breast cancer’ rdcu.be/dluy0 lead by @HRazaAliLab and myself 👉To work, immunotherapy requires certain immune cell types, in proper functional state and spatial context 🧵👇
📢(1/5) Just published in @Nature_NPJ Breast Cancer our study assessing how Oncotype DX results impact physicians' confidence and concordance in adjuvant chemotherapy recommendations for early breast cancer patients. Read more: 📌rdcu.be/dd3nv 👇👇👇
Hand-foot syndrome is a tough patient experience issue in cancer care. New RCT suggests topical diclofenac markedly reduces incidence/severity of HFS, w/less need to dose-reduce effective chemotherapy! Low cost, high impact #ASCO23 #pallonc #hapc meetings.asco.org/abstracts-pres…
📢 Historical step: first oral fecal microbiota transplant therapy approved by FDA (for recurrent Clostridioides difficile infection) Implications 👉Pave the way for broader clinical applicability such as boosting immunotherapy benefit for cancer patients nature.com/articles/d4159…
Finally out in @NEJM results from #POSITIVE trial showing that temporary interruption of #EndocrineTherapy to attempt #pregnancy is safe in #BreastCancer patients: this is wonderful news…super congrats @AnnPartridgeMD @etop_ibcsg et al! @OncoAlert #bcsm nejm.org/doi/full/10.10…
📢 First demonstration in solid tumors that an #ADC(T-DXd) after another ADC (T-DM1), despite both are targeting #HER2, improve PFS and OS in HER2+ MBC compared to standard Tx Sequencing (some) ADCs? YES👇(full text) Proud of our contribution @FAndreMD authors.elsevier.com/c/1gxxvV-4XL20…
🩺 Happy to present our work on #predictors of recurrence in hepatocellular carcinoma. Check it out! 🔬 doi.org/10.1080/147371… tandfonline.com/doi/full/10.10… #HCC #surgery #ablation @casadei_gardini
📢Intrested in #precisionimmunology in breast cancer? Check out our review in @TheBreastOnline about tissue and liquid biopsy based biomarkers for immunotherapy benefit/resistance Tailoring immunotherapy is a high unmet need Great work @LLicata88 @f_rossari @Marco52630700
💥Proud to present my first "co-first" manuscript "Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer" which has been just published in @TheBreastOnline. 💥 @BianchiniGP @LLicata88 @f_rossari sciencedirect.com/science/articl…
💥Proud to present my first "co-first" manuscript "Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer" which has been just published in @TheBreastOnline. 💥 @BianchiniGP @LLicata88 @f_rossari sciencedirect.com/science/articl…
I ricchi diventano ricchi anche perché ci sono i cretini come te.. 😡